Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study

Table 3 Prognostic factors of overall survival in 351 matched patients with gastric cancer after D2 dissection

Variable	Hazard ratio	95%CI	P value
Age at diagnosis (yr)
≤ 60	1
> 60	1.629	(1.155-2.297)	0.005
Gender
Female	1
Male	1.073	(0.731-1.576)	0.718
Tumor location
None-Cardia cancer	1
Cardia cancer	0.862	(0.605-1.227)	0.409
Tumor grade			0.888
Moderate to well	1
Moderate	1.37	(0.558-3.363)	0.492
Poor to moderate	1.283	(0.551-2.983)	0.563
Early cancer or not reported	1.972	(0.205-18.948)	0.557
Pathological stage			< 0.001
IB1	1
II	4.691	(0.994-22.128)	0.051
III	9.857	(2.174-44.686)	0.003
Lymphatic and venous invasion
No	1
Yes	0.963	(0.670-1.384)	0.837
Perineural invasion
No	1
Yes	1.679	(1.091-2.585)	0.019
Adjuvant chemotherapy
Surgery alone	1
SOX	0.475	(0.326-0.693)	< 0.001

¹Patients of stage IB (pT2N0M0) without high-risk features including poorly differentiated or higher grade cancer, lymphovascular invasion, neural invasion, or < 50 years of age were not included. SOX: S-1 plus oxaliplatin.